Anti-EGFR strategy for colorectal cancer: Searching for the real target

被引：0
|
作者：
Zaniboni, A. [1 ]
Meriggi, F. [1 ]
机构：
[1] Fdn Poliambulanza, UO Oncol Med, I-25100 Brescia, Italy
来源：
LETTERS IN DRUG DESIGN & DISCOVERY | 2006年 / 3卷 / 08期
关键词：
cetuximalb; colorectal cancer; anti-EGFR therapy;
D O I：
10.2174/157018006778194673
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The epidermal growth factor receptor (EGFR) provides survival signals and is overexpressed in the majority of colorectal cancer. Cetuximab is a recombinant human/mouse monoclonal antibody(MoAb) against EGFR, clinically active in the treatment of human colorectal cancer. Unlike the predictable correlation of response to trastuzumab, another MoAb clinically active in a subgroup of breast cancer patients expressing HER-2/neu, responses to cetuximab in EGFR-expressing colorectal cancer is not predictable.
引用
收藏
页码：541 / 543
页数：3
相关论文
共 50 条
  • [1] Optimizing Anti-EGFR Therapy in Colorectal Cancer
    Salazar, Ramon
    Ciardiello, Fortunato
    CLINICAL CANCER RESEARCH, 2015, 21 (24) : 5415 - 5416
  • [2] Real-world use of anti-EGFR therapy in metastatic colorectal cancer
    Robinson, Hannah Ruth
    Hu, Junxiao
    Balmaceda, Nicole Baranda
    Lentz, Robert William
    Toegel, Emily Baiyee
    Leal, Alexis Diane
    Kim, Sunnie S.
    Messersmith, Wells A.
    Lieu, Christopher Hanyoung
    Davis, S. Lindsey
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Anti-VEGF versus Anti-EGFR in the real world in metastatic colorectal cancer.
    Namuche, Fernando
    Flores, Claudio J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer
    Kasi, Pashtoon Murtaza
    Afable, Manuel Geroy
    Herting, Cameron
    Lukanowski, Mariusz
    Jin, Zhaohui
    ONCOLOGIST, 2023, : 1034 - 1048
  • [5] Anti-EGFR monoclonal antibody treatment in colorectal cancer
    Nature Clinical Practice Gastroenterology & Hepatology, 2005, 2 (6): : 249 - 250
  • [6] Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
    Zhao, Ben
    Wang, Lu
    Qiu, Hong
    Zhang, Mingsheng
    Sun, Li
    Peng, Ping
    Yu, Qianqian
    Yuan, Xianglin
    ONCOTARGET, 2017, 8 (03) : 3980 - 4000
  • [7] Markers of resistance to anti-EGFR therapy in colorectal cancer
    Shaib, Walid
    Mahajan, Reena
    El-Rayes, Bassel
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2013, 4 (03) : 308 - 318
  • [8] Optimization of Anti-EGFR Treatment of Advanced Colorectal Cancer
    Vecchione, Loredana
    CURRENT COLORECTAL CANCER REPORTS, 2014, 10 (03) : 263 - 271
  • [9] Integrating anti-EGFR therapies in metastatic colorectal cancer
    Haraldsdottir, Sigurdis
    Bekaii-Saab, Tanios
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2013, 4 (03) : 285 - 298
  • [10] Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis
    Schulz, Martin S.
    Wolf, Sebastian
    Struck, Vera
    Thomas, Niklas
    Husman, Gabriele
    Zeuzem, Stefan
    Koch, Christine
    Trojan, Joerg
    Schnitzbauer, Andreas Anton
    Bechstein, Wolf Otto
    Waidmann, Oliver
    CANCERS, 2022, 14 (07)
12345